About Adlai Nortye

About Adlai Nortye

Adlai Nortye is a global clinical-stage biopharmaceutical company that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye focuses on discovering and developing important new treatments for cancer with a mission to improve patient lives by identifying and developing differentiated innovative medicines that help people live better, live longer. Through close collaborations with global partners, Adlai Nortye have successfully positioned itself in the field of immuno-oncology and have several programs ongoing from early pre-clinical to ...

Management Team Board Of Directors Science Advisor
  • Carsten Lu, EMBA, CEO 
    •  Founder of Adlai Nortye
    •  Over 15 years experience of pharmaceutical R&D, manufacturing and commercialization
    •  Bachelor of Xiamen University, EMBA of CEIBS
    •  Responsible for strategic planning, investment and financing
  • Lars E. Birgerson, M.D., Ph.D., CDO 
    •  Former Senior Vice President, Medical of Bristol-Myers Squibb, USA.
    •  Physician with keen business sense and 25 years pharmaceutical industry experience in senior positions in drug development, commercial, business development and medical affairs, both globally and in the US.
    •  Proven ability to leverage business and clinical acumen into effective solutions responsive to today’s dynamic healthcare environment.
  • XIANG YIBIN FRANK ,Ph.D., Interim CSO 
    • Ph.D.of Swiss Federal Institute of Technology (ETH).

    •  Post-doctor of Harvard University.

    • Former senior medicinal chemistry director of Sanofi Genzyme.

    Over 30 years of experience and success in medicinal chemistry, drug discovery and development with global pharmaceutical and biopharmaceutical companies.

    • Initiated and managed multiple cross-functional programs and developed new and innovative drug therapies.
    Made major contributions for the identification of leading series of LTD4 antagonists, including the successful drug candidate Montelukast (Singulair).
  • YUAN RUI-RONG, M.D., President, CMO 
    •  CMO of Eisai and BeiGene; Head of Oncology and other therapeutic Areas at Daiichi-Sankyo 
    •  Senior Global Oncology Clinical Development Leader of Novartis
    •  Staff Member and Attending Physician Oncology of VA NJ Health Care System, NJ Medical School
    •  Chairman of Board Directors, Chinese American Hematologist and Oncologist Network
  • Tang Tom, M.D., MBA, SVP , Head of Development Operation 

    •  Over  20 years experience in global clinical drug development. Completed more than 50 clinical trials.

    •  Former chief medical officer and co-founder of Generon Inc. Former president of political affairs at Hutchison. Former head of clinical program at Pfizer.


  • Carsten Lu (Chairman) 


  • Victor Yang (Director) 


  • YUAN RUI-RONG (Director) 

  • Yiming Yu (Director) 


  • Shijun Feng(Director) 

  • Yuan Tian(Director) 
  • Zhiyun Yu(Director) 
  • Gangjun Zhang(Secretary of the Board) 

  • Yufen Zhao / Academician of CAS, Professor of Xiamen University 

    · Academician of Chinese Academy of Sciences.
    · Foreign academician of the Russian Academy of International Sciences.
    · Professor of Xiamen University and Tsinghua University.

    · Founder of the "Open Laboratory of State Education Commission for the life of Organic Phosphorus Chemistry"

  • Yibin Xiang (Post-doctor of Harvard University) 

    · Ph.D.of Swiss Federal Institute of Technology (ETH).
    · Post-doctor of Harvard University.
    · Former senior medicinal chemistry director of Sanofi Genzyme.
    · Over 30 years of experience and success in medicinal chemistry, drug discovery and development with global pharmaceutical and biopharmaceutical companies.

    · Initiated and managed multiple cross-functional programs and developed new and innovative drug therapies.

    · Made major contributions for the identification of leading series of LTD4 antagonists, including the successful drug candidate Montelukast (Singulair).

  • XIA WENLE / Professor of Translation Medicine, Oncology, Duke University 
    · Professor of Translation Medicine, Oncology, Duke University
    · Head of translational medicine in GSK
    · CSO of Yangtze River Pharma
    · One of inventors of EGFR/ErbB2 targeted therapies and Lapatinib
    · Responsible  for strategy of new drug R&D